Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New supplement aims to fight malnutrition in cancer patients

NCT ID NCT07035132

Disease control Sponsor: Outcomes'10 Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether a special drink made with easily digested protein and MCT oil can help improve malnutrition in cancer patients who are having radiotherapy. The study will follow 132 adults with head and neck, lung, rectal, or esophageal cancer for 12 weeks. Researchers will check weight, body mass index, and other signs of nutrition to see if the supplement helps.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 132 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

A research network

The lead sponsor is a research network or cooperative group.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Oncological patients undergoing radiotherapy, who present malnutrition or risk of malnutrition and due to the characteristics of the pathology or gastrointestinal alterations, the use of oligolimeric nutritional formulas formulated with 100% hydrolyzed serum lactoprotein and high MCT content is recommended within the usual clinical practice.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients of legal age (≥18 years). * Oncology patients (with head and neck, lung or rectal cancer) undergoing or about to start radiotherapy treatment. Patients with oesophageal cancer will also be included, as long as the patient is not undergoing PEG. * Patients who are malnourished or at risk of malnutrition according to GLIM criteria. * Patients requiring supplementation with an oligomeric formula with 100% hydrolysed serum lactoprotein and high MCT intake due to gastrointestinal disturbances (either maldigestion or maldigestion, malabsorption or dysmotility) intolerance to polymeric formulations or any other reason as considered by the physician. * Patients who, at the discretion of the investigator, have the ability to answer the questionnaires and follow the procedures detailed in the protocol. * Patients who give written informed consent to participate. Exclusion Criteria: * Patients with galactosemia, allergies and/or intolerances to lactose or any of the compounds of the formula. * Patients receiving nutritional support other than that of the study characteristics or who have received it during the last month. It will be accepted in patients who, being on a polymeric SNO, are advised to change to the oligomeric formula under study, due to gastrointestinal alterations, intolerances or any other reason considered by the doctor. * Patients who have undergone surgery in the last three months. * Patients who have received Enteral Nutrition in the last 3 months for SNG/SNJ/PEG. * Pregnant or lactating women. * Patients with advanced renal or hepatic disease (with creatinine clearance less than 45 ml/min or CP=C). * Patients with advanced neoplastic disease with life expectancy \<3 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Digestive disorders are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Digestive System Diseases digestive system disorder esophageal cancer head and neck cancer lung cancer nutritional deficiency disease rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Digestive disorders Malnutrition in elderly Oncological patients

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • HU Clinica Asturias

    Oviedo, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario San Juan de Alicante

    Alicante, Spain

  • Hospital Universitario Son Espases

    Palma de Mallorca, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.